Cardiol Therapeutics (STU:CT9) Tariff Resilience Score: 7/10 (As of Jul. 11, 2026)


STU:CT9 Cardiol Therapeutics Inc STU:CT9
32 GF Score
Price €0.87
! 3 Warning Signs
View Full Analysis

What is Cardiol Therapeutics Tariff Resilience Score?

Cardiol Therapeutics STU:CT9 +0.23% 32 Tariff Resilience Score is 7 as of Jul. 11, 2026. GuruFocus rates STU:CT9 with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,029 Drug Manufacturers companies, Cardiol Therapeutics ranks better than 97.08% on this metric.

Cardiol Therapeutics has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Cardiol Therapeutics has Cardiol Therapeutics, operating in pharmaceuticals, faces minimal tariff impact. Manufacturing is often localized, and essential medicines may receive exemptions, enhancing resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Cardiol Therapeutics might have Highly Resilient.

Cardiol Therapeutics  (STU:CT9) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Cardiol Therapeutics Tariff Resilience Score Related Terms

STU:CT9 vs ZTS, UTHR: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cardiol Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardiol Therapeutics Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cardiol Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Cardiol Therapeutics's Tariff Resilience Score falls into.


STU:CT9
32GF Score
Cardiol Therapeutics Inc STU:CT9
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Cardiol Therapeutics (STU:CT9) has a Tariff Resilience Score of 7 as of Jul. 11, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Cardiol Therapeutics ranks #30 out of 1029 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Cardiol Therapeutics' Tariff Resilience Score too high?
Cardiol Therapeutics' current Tariff Resilience Score is 7. Based on the distribution chart, Cardiol Therapeutics ranks #30 out of 1029 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cardiol Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Cardiol Therapeutics' Tariff Resilience Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cardiol Therapeutics ranks #30 out of 1029 companies for Tariff Resilience Score. This places Cardiol Therapeutics in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Cardiol Therapeutics's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiol Therapeutics stock overvalued right now?
Cardiol Therapeutics (STU:CT9) has a current Tariff Resilience Score of 7. The current Tariff Resilience Score is 7. Cardiol Therapeutics' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Cardiol Therapeutics (STU:CT9), the current Tariff Resilience Score is 7 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiol Therapeutics Business Description

Other Exchanges CRDL:USACRDL:Canada
Address 2265 Upper Middle Road East, Suite 602, Oakville, ON, CAN, L6H 0G5
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
32GF Score

Get the complete analysis for STU:CT9

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.87
Price